oxybutynin and Urinary Bladder, Neurogenic studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Urinary Bladder, Neurogenic: Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.

Research Excerpts

Excerpt	Relevance	Reference
"The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence."	7.68	[Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence]. ( Hashimoto, H; Inagaki, N; Ohashi, K; Osanai, H; Yachiku, S; Yamaguchi, S; Yamauchi, K, 1990)
"Nine patients with persistent urinary incontinence due to neurogenic bladder and intolerable systemic side effects on oral anticholinergic agents were treated with intravesical instillation of oxybutynin hydrochloride."	5.08	[The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization]. ( Ishiura, Y; Nakamura, Y; Ohkawa, M; Yokoyama, O, 1995)
"Oxybutynin hydrochloride (Pollakisu tablets) was administered at a daily dose of 6 or 9 mg to 75 elderly patients with urinary tract disorders, including neurogenic bladder and unstable bladder, with chief complaints of pollakisuria, urgency on urination and urinary incontinence."	5.07	[Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly]. ( Hisazumi, H; Nakajima, K; Nihino, A; Uchibayashi, T, 1991)
"Intravesical oxybutynin hydrochloride was administered to 17 patients with a neuropathic bladder (myelomeningocele in 15 and spinal cord tumour in two) and urinary incontinence refractory to intermittent catheterisation."	3.69	Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. ( Chiba, K; Kaneko, S; Miyata, M; Mizunaga, M; Yachiku, S, 1994)
"The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence."	3.68	[Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence]. ( Hashimoto, H; Inagaki, N; Ohashi, K; Osanai, H; Yachiku, S; Yamaguchi, S; Yamauchi, K, 1990)
"Intravesical oxybutynin chloride was administered to 10 children with neurogenic bladder (myelomeningocele in 9 and imperforate anus in 1) and urinary incontinence refractory to regimens of intermittent catheterization and oral anticholinergic medication."	3.68	The use of intravesical oxybutynin chloride in children with neurogenic bladder. ( Fera, M; Greenfield, SP, 1991)
"Fesoterodine has a favorable benefit-risk profile in 6‒<18-year-old patients with NDO and may represent an additional option for pediatric NDO treatment."	3.30	Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. ( Crook, TJ; Darekar, A; Jones, P; Kitta, T; Lindsay, M; Malhotra, B; Mallen, S; Nieto, A; Shahin, MH, 2023)
" Adverse drug reactions (ADR) were collected and an evaluation of anticholinergic effects was conducted."	2.82	Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial. ( Albrecht, U; Reitz, A; Schnitker, J; Schröder, A; Stein, R, 2016)
"Gabapentin was better tolerated than oxybutynin."	2.82	Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida - a randomized controlled study. ( Bawa, M; Dash, V; Kanojia, RP; Mahajan, JK; Rao, KL; Samujh, R, 2016)
" There were 12 treatment related adverse events noted with transdermal oxybutynin (mild skin reaction) and 1 with oral oxybutynin (vasodilatation)."	2.74	Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. ( Cartwright, PC; Coplen, DE; Finan, E; Hoel, G; Kogan, BA; Volinn, W, 2009)
"Patients with neurogenic bladder dysfunction demonstrate an insufficient treatment outcome under dosage-escalated monotherapy."	2.73	Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. ( Amend, B; Hennenlotter, J; Horstmann, M; Schäfer, T; Sievert, KD; Stenzl, A, 2008)
"or oxybutynin 5mg t."	2.73	Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. ( Arnold, EP; Kramer, G; Mürtz, G; Schnabel, F; Stöhrer, M; Wyndaele, JJ, 2007)
" All patients chose a final effective dosage of greater than 10 mg, with 4 patients taking the maximum of 30 mg per day."	2.71	Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. ( Chancellor, MB; Erickson, JR; Horton, J; McDermott, C; O'Leary, M; Smith, CP, 2003)
"Aggressive dosing of OXY-XL is safe and effective in patients with neurogenic bladder."	2.71	Can higher doses of oxybutynin improve efficacy in neurogenic bladder? ( Bennett, N; Chancellor, MB; Erickson, JR; O'Leary, M; Patel, AS; Xavier, M, 2004)
"Modified intravesical oxybutynin is an effective and relatively safe option of therapy for overactive bladder patients."	2.71	Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. ( Miyagawa, I; Otsubo, K; Saito, M; Satoh, K; Tabuchi, F; Watanabe, T, 2004)
"Fifteen spina bifida patients, aged between 1 and 12 years, all on a regime of clean intermittent catheterisation (CIC) and oxybutynin since shortly after birth, underwent three consecutive urodynamic studies (UDS)."	2.71	Detrusor overactivity in spina bifida: how long does it need to be treated? ( Ab, E; de Jong, TP; Dik, P; Klijn, AJ; van Gool, JD, 2004)
" Tolterodine at the recommended dosage of 2 mg twice daily improves incontinence and bladder volumes compared with placebo, and without significant dry mouth."	2.71	Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. ( Bard, RJ; Casey, AR; Ethans, KD; Nance, PW; Schryvers, OI, 2004)
"All 3 formulations of oxybutynin are safe and effective in children with neurogenic bladder dysfunction."	2.71	Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. ( Adams, RC; Albrecht, D; de Jong, TP; Franco, I; Grady, R; Horowitz, M; Lindert, K, 2005)
" The third, open study period was designed for pharmacokinetic purposes with all patients on the active drug."	2.70	Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. ( Hakonen, T; Lehtoranta, K; Lukkari-Lax, E; Tainio, H; Tammela, TL, 2002)
" The topical oxybutynin therapy dosage (A) was efficient in 66% of our selected patients, the escalating dosage titration (B) could increase the efficiency to 87%."	2.69	Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. ( Dörsam, J; Gerner, HJ; Haferkamp, A; Staehler, G, 2000)
" Tolterodine was significantly better tolerated than oxybutynin when adverse events (particularly frequency and intensity of dry mouth), dose reduction and patient withdrawals were considered."	2.69	Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. ( Appell, RA; Drutz, HP; Gleason, D; Klimberg, I; Radomski, S, 1999)
" Safety and tolerability were assessed from adverse events and laboratory measures."	2.68	Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. ( Appell, RA, 1997)
"The efficacy and safety of long-term administration of oxybutynin hydrochloride in patients with neurogenic bladder and unstable bladder, who complained of urinary frequency, urgency and incontinence, and whose bladder was proved to be uninhibited, reflex, and/or low compliant, were studied at the multi-center hospitals, and the following results were obtained."	2.66	[Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder]. ( Mizutani, S; Ogawa, T; Sakurai, T; Sonoda, T; Tsujimoto, Y; Yamada, K, 1989)
"Clinical effects of oxybutynin hydrochloride on lower urinary tract function at a dosage of 2 mg given orally three times daily (6 mg/day), were studied on 10 patients with neurogenic bladder by cystometry and measurement of residual urine."	2.66	[Clinical effects of oxybutynin hydrochloride on neurogenic bladder]. ( Nakamura, R; Toma, H, 1986)
"Pediatric neuropathic bladder dysfunction can cause irreversible renal damage and urinary incontinence."	2.45	Intravesical oxybutynin in the pediatric neurogenic bladder. ( Lazarus, J, 2009)
"Children with neurogenic bladder and poor bladder compliance are usually treated with bladder catheterization and oral anticholinergic medication."	2.44	Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. ( Barrowman, N; Guerra, LA; Leonard, M; Moher, D; Pike, J; Sampson, M, 2008)
" They represent an improvement compared with transdermal delivery by patches because they offer more dosage flexibility, less irritation potential and a better cosmetic appearance."	2.43	Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. ( Alberti, I; Carrara, DN; Grenier, A; Kraus, H, 2005)
"Daytime wetting is a common problem with various causes that can usually be identified through a careful history, thorough physical examination, and urinalysis."	2.43	An approach to daytime wetting in children. ( Leung, AK; Robson, WL, 2006)
" In direct comparison to oxybutynin IR, oxybutynin ER has an increased oral bioavailability for the parent compound oxybutynin which is accompanied by a reduced bioavailability for the active metabolite N-desethyl-oxybutynin."	2.41	A benefit-risk assessment of extended-release oxybutynin. ( Michel, MC, 2002)
" Controlled drug delivery systems seen in commercially available OAB formulations alter the pharmacokinetics of antimuscarinic medications in ways that maintain efficacy and allow once-daily dosing and reduction of adverse events."	2.41	New perspectives on the overactive bladder: pharmacokinetics and bioavailability. ( Gupta, S; Mori, T; Sathyan, G, 2002)
"The wide dosing variability and high DLPPs despite maximal dosing indicate a need for further investigation of oxybutynin's bioavailability in this population compared to its side effects and clinical outcomes."	1.72	Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder. ( Campbell, JG; Koenig, JF; Malik, MF; McLaughlin, MJ; Randall, JH, 2022)
"A low-pressure bladder in children with neuropathic bladder dysfunction can be achieved using anticholinergic medication."	1.51	Can Oral Fesoterodine Be an Alternative for Intravesical Oxybutynin Instillations in Children with Neuropathic Bladder Dysfunction? ( Bogaert, G; De Coster, K; Jansen, K; van den Heijkant, M, 2019)
"Records relevant to OC use for neurogenic bladder were gathered and scrutinized from four specialized clinics for pediatric urology."	1.40	Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study. ( Baek, M; Han, SW; Kim, KR; Kim, KS; Lee, JH; Lee, YS; Park, K; Song, SH, 2014)
" In 11 patients, oxybutynin could be stopped, and in 2 the dosage could be reduced to once daily."	1.39	Detrusorectomy reduces the need for augmentation and use of antimuscarinics in children with neuropathic bladders. ( Chrzan, R; de Jong, TP; Dik, P; Klijn, AJ; Kuijper, CF, 2013)
"Children with open and closed spinal dysraphism were recruited from 2 pediatric hospitals, 1 in Amsterdam and 1 in Utrecht, The Netherlands."	1.39	Behavioral effects of long-term antimuscarinic use in patients with spinal dysraphism: a case control study. ( Chrzan, RJ; de Jong, TP; de Kort, LM; Dik, P; Huisman, J; Kuijper, CF; Veenboer, PW, 2013)
"Oxybutynin-TDS was efficacious in spinal cord injury patients with neurogenic detrusor overactivity and was well tolerated at up to 3 times the standard dose."	1.35	Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. ( Foote, JE; Kennelly, MJ; Lemack, GE; Trop, CS, 2009)
"Propiverine was better tolerated than oxybutynin, having fewer adverse drug reactions (9."	1.35	Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Domurath, B; Henne, T; Körner, I; Madersbacher, H; Mürtz, G; Niedeggen, A; Nounla, J; Pannek, J; Schulte-Baukloh, H; Schultz-Lampel, D; Strugala, G, 2009)
"Others 7 patients had non neurogenic bladder secondary to: posterior urethral valvulas (n=1), valvula-like syndrome (n=4), post-surgery of neonatal giant bladder diverticulum (n=1) and Prune-Belly syndrome (n=1)."	1.33	[Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder]. ( Aparicio, C; Blanco, T; Cañizo, A; Cebrían, J; Fernández, A; Hernández, E; Luque Mialdea, R; Martín-Crespo, R; Sánchez, O, 2005)
"To evaluate type of neurogenic bladder and to observe changes of autonomous detrusor contraction (ADC) after the normalization of the compliance and capacity of the bladder in cauda equina injury."	1.31	Significance of low compliance bladder in cauda equina injury. ( Kim, HJ; Lee, IY; Park, CI; Shin, JC, 2002)
"The study comprised 225 children with a neurogenic bladder from MMC who were evaluated with urodynamic testing and voiding cysto-urethrography to identify those at high risk of upper tract damage."	1.31	Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. ( D'Aleo, CM; Ferrara, P; Salvaggio, E; Salvatore, S; Tarquini, E, 2001)
"Extended-release oxybutynin is safe and efficacious in children."	1.31	Preliminary study of the safety and efficacy of extended-release oxybutynin in children. ( Kogan, BA; Youdim, K, 2002)
"The etiologies and forms of congenital neuropathic bladder are described: contractile (25%), acontractile (15%), and intermediate (60%)."	1.31	Assessment and conservative management of the neuropathic bladder. ( Rickwood, AM, 2002)
"Patients requiring CIC for neurogenic bladder but with incontinence that was unresponsive to standard oral therapy or that was associated with severe systemic side effects were studied over a 1-year period."	1.30	Intravesical therapy for the treatment of neurogenic bladder in children. ( Barker, AP; Chauvel, PJ; Holland, AJ; King, PA; McKnight, DL; O'Neill, MK, 1997)
" In addition, 4 healthy dogs underwent intravesical instillation for pharmacokinetic studies."	1.28	The pharmacokinetics of intravesical and oral oxybutynin chloride. ( Kogan, BA; Massad, CA; Trigo-Rocha, FE, 1992)
"Management of neuropathic bladder aims to maintain renal function and to secure appliance-free continence; because of recent advances, both objectives are theoretically attainable."	1.28	Current management of childhood neuropathic bladder: review of 156 cases. ( Arnold, AJ; Rickwood, AM, 1990)
"Of 21 patients treated, 9 had neurogenic bladder and 10 had unstable bladder."	1.28	[Clinical effect of oxybutynin hydrochloride (1 mg/tablet)]. ( Fujino, A; Koshiba, K; Kubo, S; Mashimo, S; Yokoyama, E, 1990)
") was not statistically different than the mean peak level reported after the same dosage in young healthy men (8."	1.27	Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. ( Blaustein, J; Connor, A; Orzeck, S; Ouslander, JG; Yong, CL, 1988)
"Oxybutynin chloride has been clinically used for the relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflex neurogenic bladder in the USA."	1.27	Clinical reevaluation of the effect of oxybutynin chloride on uninhibited neurogenic and reflex neurogenic bladder. ( Abe, S; Kanda, T; Kawabe, K; Tei, K, 1986)

Research

Studies (121)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Average Number of Catheterizations Without Leaking Per Day

Timeframe	Studies, this research(%)	All Research%
pre-1990	21 (17.36)	18.7374
1990's	37 (30.58)	18.2507
2000's	41 (33.88)	29.6817
2010's	19 (15.70)	24.3611
2020's	3 (2.48)	2.80

Authors	Studies
Sonda, S	1
Katayama, K	1
Fujio, M	1
Sakashita, H	1
Inaba, K	1
Asano, K	1
Akira, T	1
Malik, MF	1
Randall, JH	1
Campbell, JG	1
McLaughlin, MJ	1
Koenig, JF	1
Kitta, T	2
Darekar, A	2
Malhotra, B	2
Shahin, MH	2
Jones, P	2
Lindsay, M	2
Mallen, S	2
Nieto, A	2
Crook, TJ	2
Lee, AS	1
Viseshsindh, W	1
Long, CJ	1
Frazier, JR	1
Moran, MH	1
Zderic, SA	1
Weiss, DA	1
Beckers, GMA	1
van Moorselaar, RJA	1
Ferreira, RS	1
D'Ancona, CAL	1
Oelke, M	1
Carneiro, MR	1
van den Heijkant, M	1
De Coster, K	1
Jansen, K	2
Bogaert, G	1
Baek, M	2
Kang, JY	1
Jeong, J	1
Kim, DK	1
Kim, KM	1
Butler, L	1
Keys, C	1
Lam, JP	1
Veenboer, PW	1
Huisman, J	1
Chrzan, RJ	1
Kuijper, CF	2
Dik, P	3
de Kort, LM	1
de Jong, TP	4
Austin, PF	1
Humblet, M	1
Verpoorten, C	4
Christiaens, MH	1
Hirche, H	1
Buyse, G	4
van Gool, JD	2
Snodgrass, W	1
Villaneuva, C	1
Jacobs, M	1
Gargollo, P	1
Momper, JD	1
Karesh, A	1
Green, DJ	1
Hirsch, M	1
Khurana, M	1
Lee, J	1
Kim, MJ	1
Mulugeta, Y	1
Sachs, HC	1
Yao, L	1
Burckart, GJ	1
Álvares, RA	1
Araújo, ID	1
Sanches, MD	1
Lee, JH	1
Kim, KR	1
Lee, YS	1
Han, SW	1
Kim, KS	1
Song, SH	1
Park, K	1
Schröder, A	1
Albrecht, U	1
Schnitker, J	1
Reitz, A	1
Stein, R	1
Wada, N	1
Shimizu, T	1
Takai, S	1
Shimizu, N	1
Tyagi, P	1
Kakizaki, H	1
Yoshimura, N	1
Dash, V	1
Bawa, M	1
Mahajan, JK	1
Kanojia, RP	1
Samujh, R	1
Rao, KL	1
Guerra, LA	1
Moher, D	1
Sampson, M	1
Barrowman, N	1
Pike, J	1
Leonard, M	1
Madersbacher, H	2
Mürtz, G	2
Alloussi, S	1
Domurath, B	1
Henne, T	1
Körner, I	1
Niedeggen, A	1
Nounla, J	1
Pannek, J	2
Schulte-Baukloh, H	1
Schultz-Lampel, D	1
Bock, P	1
Strugala, G	1
Kennelly, MJ	1
Lemack, GE	1
Foote, JE	1
Trop, CS	1
Cartwright, PC	1
Coplen, DE	1
Kogan, BA	5
Volinn, W	1
Finan, E	1
Hoel, G	1
Van Meel, TD	1
De Wachter, S	1
Wyndaele, JJ	2
Lazarus, J	1
Staskin, DR	2
Salvatore, S	2
Wang, QW	1
Song, DK	1
Zhang, XP	1
Wu, YD	1
Zhang, RL	1
Wei, JX	1
Wen, JG	1
Chrzan, R	1
Klijn, AJ	2
Sussman, D	1
Garely, A	1
Michel, MC	1
Aslan, AR	1
Shin, JC	1
Park, CI	1
Kim, HJ	1
Lee, IY	1
Gupta, S	1
Sathyan, G	1
Mori, T	1
Shimizu, I	1
Kawashima, K	1
Ishii, D	1
Oka, M	1
O'Leary, M	2
Erickson, JR	2
Smith, CP	1
McDermott, C	1
Horton, J	1
Chancellor, MB	4
Wimett, L	1
Laustsen, G	1
Bennett, N	1
Patel, AS	1
Xavier, M	1
Saito, M	1
Watanabe, T	2
Tabuchi, F	1
Otsubo, K	1
Satoh, K	1
Miyagawa, I	1
Puri, A	1
Bajpai, M	1
Gupta, AK	1
Ab, E	1
Ethans, KD	1
Nance, PW	1
Bard, RJ	1
Casey, AR	1
Schryvers, OI	1
Franco, I	1
Horowitz, M	1
Grady, R	1
Adams, RC	1
Lindert, K	1
Albrecht, D	2
Luque Mialdea, R	1
Martín-Crespo, R	1
Hernández, E	1
Sánchez, O	1
Cañizo, A	1
Fernández, A	1
Aparicio, C	1
Blanco, T	1
Cebrían, J	1
Mazo, EB	1
Krivoborodov, GG	1
Alberti, I	1
Grenier, A	1
Kraus, H	1
Carrara, DN	1
Sahai, A	1
Khan, MS	1
Arya, M	1
John, J	1
Singh, R	1
Patel, HR	1
Stöhrer, M	1
Kramer, G	1
Schnabel, F	1
Arnold, EP	1
Brubaker, L	1
Chapple, C	1
Coyne, KS	1
Kopp, Z	1
Robson, WL	1
Leung, AK	1
Fader, M	1
Glickman, S	1
Haggar, V	1
Barton, R	1
Brooks, R	1
Malone-Lee, J	2
Almodhen, F	1
Capolicchio, JP	1
Jednak, R	1
El Sherbiny, M	1
Wan, J	2
Rickman, C	1
George, J	1
Tharion, G	1
Richar, J	1
Macaden, AS	1
Thomas, R	1
Bhattacharji, S	1
Amend, B	1
Hennenlotter, J	1
Schäfer, T	1
Horstmann, M	1
Stenzl, A	1
Sievert, KD	1
McGuire, EJ	1
Savastano, JA	1
Riva, D	1
Casolati, E	1
Koff, SA	2
Murtagh, DS	1
Murtagh, D	1
Moisey, CU	2
Stephenson, TP	2
Brendler, CB	3
Bary, PR	1
Brooks, ME	1
Braf, ZF	1
Yokoyama, O	1
Ishiura, Y	1
Nakamura, Y	1
Ohkawa, M	1
Rivas, DA	2
Huang, B	1
Salzman, SK	1
Zerin, JM	1
DiPietro, MA	1
Ritchey, ML	1
Bloom, DA	1
Mizunaga, M	1
Miyata, M	1
Kaneko, S	1
Yachiku, S	2
Chiba, K	1
Connor, JP	1
Betrus, G	1
Fleming, P	2
Perlmutter, AD	2
Reitelman, C	1
Prasad, KV	1
Vaidyanathan, S	1
López Pereira, P	1
Martínez, MJ	1
Muguerza, R	1
Jaureguizar, E	1
Knoll, M	1
Kaplinsky, R	1
Greenfield, S	1
Fera, M	2
Vereecken, R	2
Casaer, P	3
Painter, KA	1
Vates, TS	1
Bukowski, TP	1
Freedman, AL	1
Smith, CA	1
Gonzalez, R	1
Szollar, SM	1
Lee, SM	1
Von Zweigbergk, M	1
Nordin, B	1
Jonsson, S	1
Palmer, LS	1
Zebold, K	1
Firlit, CF	1
Kaplan, WE	1
Shenot, PJ	1
Kumon, H	1
Figueroa, TE	1
Holland, AJ	1
King, PA	1
Chauvel, PJ	1
O'Neill, MK	1
McKnight, DL	1
Barker, AP	1
Kim, YH	1
Bird, ET	1
Priebe, M	1
Boone, TB	1
Appell, RA	3
Vaidyananthan, S	1
Soni, BM	1
Brown, E	1
Sett, P	1
Krishnan, KR	1
Bingley, J	1
Markey, S	1
Amark, P	2
Bussman, G	2
Eksborg, S	2
Waldeck, K	1
Björk, H	1
Andersson, KE	1
Juneskans, O	1
Palm, C	1
Hashimoto, K	1
Ohnishi, N	1
Esa, A	1
Sugiyama, T	1
Park, Y	1
Kurita, T	1
Kaefer, M	1
Pabby, A	1
Kelly, M	1
Darbey, M	1
Bauer, SB	2
Drutz, HP	1
Gleason, D	1
Klimberg, I	1
Radomski, S	1
Sommerfeld, HJ	1
Bötel, U	1
Senge, T	1
Haferkamp, A	1
Staehler, G	1
Gerner, HJ	1
Dörsam, J	1
Sand, P	1
Dmochowski, R	1
Anderson, R	1
Zinner, N	1
Lama, D	1
Roach, M	1
Miklos, J	1
Saltzstein, D	1
Boone, T	1
Shaffu, B	1
Anand, C	1
Powell, C	1
Ferrara, P	1
D'Aleo, CM	1
Tarquini, E	1
Salvaggio, E	1
Di Stasi, SM	1
Giannantoni, A	1
Navarra, P	1
Capelli, G	1
Storti, L	1
Porena, M	1
Stephen, RL	1
Youdim, K	1
Rickwood, AM	2
Lehtoranta, K	1
Tainio, H	1
Lukkari-Lax, E	1
Hakonen, T	1
Tammela, TL	1
Finkbeiner, AE	1
Bissada, NK	1
Welch, LT	1
Lin-Dyken, DC	1
Wolraich, ML	1
Hawtrey, CE	1
Doja, MS	1
Belloli, G	1
Campobasso, P	1
Mercurella, A	1
Kasabian, NG	1
Dyro, FM	1
Colodny, AH	1
Mandell, J	1
Retik, AB	1
Massad, CA	1
Trigo-Rocha, FE	1
Uchibayashi, T	1
Nakajima, K	1
Nihino, A	1
Hisazumi, H	1
Greenfield, SP	1
Yamauchi, K	1
Ohashi, K	1
Osanai, H	1
Inagaki, N	1
Yamaguchi, S	1
Hashimoto, H	1
Nagy, F	1
Hamvas, A	1
Frang, D	1
Arnold, AJ	1
Yokoyama, E	1
Fujino, A	1
Kubo, S	1
Mashimo, S	1
Koshiba, K	1
Baskin, LS	1
Benard, F	1
Malkowicz, SB	1
Wein, AJ	2
Ruggieri, MR	1
Levin, RM	2
Kato, K	2
Kitada, S	1
Chun, A	1
Sonoda, T	1
Sakurai, T	1
Yamada, K	1
Mizutani, S	1
Tsujimoto, Y	1
Ogawa, T	1
Radebaugh, LC	1
Mohler, JL	1
Ouslander, JG	1
Blaustein, J	1
Connor, A	1
Orzeck, S	1
Yong, CL	1
Goto, M	1
Kondo, A	1
Otani, T	1
Takita, T	1
Kobayashi, M	1
Toma, H	1
Nakamura, R	1
Aubert, D	1
Cencig, P	1
Royer, M	1
Takimoto, Y	1
Kiyotaki, S	1
Kawazoe, K	1
Fuse, T	1
Kitamura, K	1
Yamamoto, T	1
Satoh, Y	1
Okada, K	1
Kishimoto, T	1
Gajewski, JB	1
Awad, SA	1
Kawabe, K	1
Abe, S	1
Kanda, T	1
Tei, K	1
Tempkin, A	1
Sullivan, G	1
Paldi, J	1
Perkash, I	1
Homsy, YL	1
Nsouli, I	1
Hamburger, B	1
Laberge, I	1
Schick, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury[NCT00224029]	Phase 4	24 participants (Actual)	Interventional	2004-12-31	Completed
Oxybutynin for Post-surgical Bladder Pain and Urgency[NCT03952299]	Phase 3	100 participants (Anticipated)	Interventional	2021-09-01	Recruiting
A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients[NCT01192568]	Phase 4	19 participants (Actual)	Interventional	2011-05-02	Active, not recruiting
A Multi-Center, Open-Label (OL), Active-Controlled, Dose-Titration Study Evaluating the Safety, Efficacy and PK of Oxybutynin Transdermal Systems in the Treatment of Detrusor Overactivity in Pediatric Patients[NCT00224016]	Phase 4	57 participants (Actual)	Interventional	2004-12-31	Completed
Peppermint Oil as an Alternative Treatment for Children With Bladder and Bowel Dysfunction: A Prospective Study[NCT05613153]		30 participants (Anticipated)	Interventional	2022-11-01	Enrolling by invitation
A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04)[NCT01050114]	Phase 3	36 participants (Anticipated)	Interventional	2013-08-31	Recruiting
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients - Clinical Effects and Investigating Mechanism of Action[NCT01682603]	Phase 2	34 participants (Actual)	Interventional	2012-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Baseline in number of daily catheterizations without leaking per day as recorded in a 3-day urinary diary. (NCT00224029)
Timeframe: 8 weeks

Average Catheterization Urine Volume

Intervention	Number of Dry Catheterizations per Day (Mean)
	Baseline at Week 0	Change from baseline at Week 8
Oxybutynin Transdermal System	2.4	1.5

Change from baseline in average volume of urine collected by catheterization (NCT00224016)
Timeframe: 14 weeks

Catheterizations Without Leakage

Autonomic Dysreflexia

Net Change of the Bladder Compliance

Intervention	mL (Mean)
	Baseline Catheterization Volume	Change from Baseline in Cath Volume
Oral Oxybutynin	114.0	52.4
Oxybutynin TDS	95.3	30.0

Intervention	% of participants (Mean)
	Baseline % Catheterizations without leakage	Endpoint % Catheterizations without leakage
Oral Oxybutynin	38.1	72.6
Oxybutynin TDS	28.7	53.8

Intervention	participants (Number)
	Post-Autonomic dysreflexia	Post-Non Autonomic dysreflexia
Pre-Autonomic Dysreflexia	5	6
Pre-Non Autonomic Dysreflexia	1	22

"Bladder compliance is the result of a mathematical calculation of the volume required for a unit rise of pressure measured during a cystometric filling.~Bladder compliance is calculated by dividing the volume change by the change in bladder pressure (mL/cmH2O).~Efficacy:~Net change of the bladder compliance from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Cystometric Bladder Capacity (CBC)

Intervention	mL/cmH2O (Mean)
	Baseline	12 months
Botulinum Toxin A	30.6	29.0

"Efficacy:~Net change of the cystometric bladder capacity (CBC) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Detrusor Pressure (Pdet)

Intervention	mL (Mean)
	Baseline	12 months
Botulinum Toxin A	305.9	437.6

"Efficacy:~Net change of the detrusor pressure (Pdet) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Incontinence Impact Questionnaire (IIQ-7)

Intervention	cmH2O (Mean)
	Baseline	12 months
Botulinum Toxin A	36.1	12.9

"Efficacy:~Net change of the Incontinence Impact Questionnaire (IIQ-7) from baseline and 12 months.~The IIQ-7 is a 7-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~Total IIQ-7 score ranges = 0 to 21 The total IIQ-7 score can therefore range from 0 to 21 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Maximum Flow Rate (Qmax)

Intervention	units on a scale (Mean)
	Baseline	12 months
Botulinum Toxin A	11.9	5.57

"Efficacy:~Net change of the maximum flow rate (Qmax) from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Postvoid Residual Volume (PVR)

Intervention	mL/s (Mean)
	Baseline	12 months
Botulinum Toxin A	4.56	3.54

"Efficacy:~Net change of the postvoid residual volume (PVR) from baseline and 12 months~Results:~Botulinum toxin A injection have increased postvoid residual urine volume in patients treated for bladder dysfunction.~Treat only patients who are willing and able to initiate catheterization post-treatment, if required, for urinary retention.~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Quality of Life Index (QoL-I)

Intervention	mL (Mean)
	Baseline	12 months
Botulinum Toxin A	226.3	378.5

"Efficacy:~Net change of the quality of life index (QoL-I) from baseline and 12 months. The QoL-I on a 7-point scale ranging from 0 Delighted to 6 Terrible. The QoL-I ranges 0 to 6~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Urinary Distress Inventory (UDI-6)

Intervention	units on a scale (Mean)
	Baseline	12 months
Botulinum Toxin A	4.00	2.21

"Efficacy:~Net change of the UrinaryDdistress Inventory (UDI-6) from baseline and 12 months.~The UDI-6 is a 6-item short forms on a 4-point scale ranging from 0 Not at all to 3 Greatly.~The total UDI-6 score can therefore range from 0 to 18 (asymptomatic to very symptomatic).~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Net Change of the Void Volume

Intervention	units on a scale (Mean)
	Baseline	12 months
Botulinum Toxin A	10.4	7.43

"Efficacy:~Net change of the void volume from baseline and 12 months~Safety:~Systemic adverse events" (NCT01682603)
Timeframe: Baseline and 12 months

Article	Year
Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Administration, Intravesical; Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Uri	2008
Intravesical oxybutynin in the pediatric neurogenic bladder. Nature reviews. Urology, 2009, Volume: 6, Issue:12 Topics: Administration, Intravesical; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder	2009
Oxybutynin topical and transdermal formulations: an update. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:6 Topics: Administration, Cutaneous; Administration, Topical; Cholinergic Antagonists; Gels; Humans; Mandelic	2010
A benefit-risk assessment of extended-release oxybutynin. Drug safety, 2002, Volume: 25, Issue:12 Topics: Delayed-Action Preparations; Humans; Mandelic Acids; Parasympatholytics; Randomized Controlled Trial	2002
Conservative management in neurogenic bladder dysfunction. Current opinion in urology, 2002, Volume: 12, Issue:6 Topics: Anti-Dyskinesia Agents; Benzhydryl Compounds; Biofeedback, Psychology; Botulinum Toxins; Child; Chil	2002
New perspectives on the overactive bladder: pharmacokinetics and bioavailability. Urology, 2002, Volume: 60, Issue:5 Suppl 1 Topics: Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Biological Availability; Chol	2002
Oxytrol approved for overactive bladder. The Nurse practitioner, 2003, Volume: 28, Issue:8 Topics: Administration, Cutaneous; Clinical Trials as Topic; Drug Approval; Humans; Mandelic Acids; United S	2003
Bilateral spontaneous perinephric urinomas: case report and review of the literature. Urology, 2004, Volume: 64, Issue:3 Topics: Child; Combined Modality Therapy; Cysts; Drainage; Humans; Male; Mandelic Acids; Pressure; Ultrasono	2004
[Neurological aspect of the hyperactive urinary bladder syndrome]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2005, Volume: 105, Issue:7 Topics: Benzilates; Brain; Brain Diseases; Cerebrovascular Circulation; Humans; Mandelic Acids; Muscarinic A	2005
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert opinion on drug delivery, 2005, Volume: 2, Issue:5 Topics: Administration, Cutaneous; Alprazolam; Animals; Anti-Anxiety Agents; Drug Delivery Systems; Estradio	2005
The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:5 Topics: Administration, Cutaneous; Administration, Intravesical; Administration, Oral; Algorithms; Animals;	2006
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology, 2006, Volume: 68, Issue:2 Suppl Topics: Benzhydryl Compounds; Clinical Trials as Topic; Cresols; Health Status; Humans; Mandelic Acids; Musc	2006
An approach to daytime wetting in children. Advances in pediatrics, 2006, Volume: 53 Topics: Arousal; Benzhydryl Compounds; Child; Child, Preschool; Constipation; Cresols; Diurnal Enuresis; Hum	2006
Uropharmacology: part VI. Parasympathetic depressants. Urology, 1977, Volume: 10, Issue:5 Topics: Acetylcholine; Atropine; Belladonna Alkaloids; Benactyzine; Cyclohexanes; Hemicholinium 3; Humans; M	1977

Article	Year
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. Journal of pediatric urology, 2023, Volume: 19, Issue:2 Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde	2023
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. Journal of pediatric urology, 2023, Volume: 19, Issue:2 Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde	2023
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. Journal of pediatric urology, 2023, Volume: 19, Issue:2 Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde	2023
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. Journal of pediatric urology, 2023, Volume: 19, Issue:2 Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde	2023
Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. Einstein (Sao Paulo, Brazil), 2018, Aug-06, Volume: 16, Issue:3 Topics: Acetylcholine Release Inhibitors; Administration, Oral; Adult; Botulinum Toxins, Type A; Female; Fol	2018
Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial. Neurourology and urodynamics, 2016, Volume: 35, Issue:5 Topics: Administration, Intravesical; Administration, Oral; Adult; Female; Humans; Male; Mandelic Acids; Pro	2016
Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida - a randomized controlled study. Journal of pediatric surgery, 2016, Volume: 51, Issue:12 Topics: Adolescent; Amines; Child; Child, Preschool; Cholinergic Antagonists; Cyclohexanecarboxylic Acids; F	2016
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology, 2009, Volume: 182, Issue:4 Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A	2009
Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Current medical research and opinion, 2002, Volume: 18, Issue:4 Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Delayed-A	2002
Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. The journal of spinal cord medicine, 2003,Summer, Volume: 26, Issue:2 Topics: Adult; Aged; Autonomic Dysreflexia; Delayed-Action Preparations; Dose-Response Relationship, Drug; F	2003
Can higher doses of oxybutynin improve efficacy in neurogenic bladder? The Journal of urology, 2004, Volume: 171, Issue:2 Pt 1 Topics: Adult; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Prospective Studie	2004
Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. International journal of urology : official journal of the Japanese Urological Association, 2004, Volume: 11, Issue:8 Topics: Administration, Intravesical; Adolescent; Aged; Cellulose; Drug Therapy, Combination; Female; Follow	2004
Detrusor overactivity in spina bifida: how long does it need to be treated? Neurourology and urodynamics, 2004, Volume: 23, Issue:7 Topics: Child; Child, Preschool; Cholinergic Antagonists; Compliance; Female; Humans; Infant; Infant, Newbor	2004
Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. The journal of spinal cord medicine, 2004, Volume: 27, Issue:3 Topics: Adult; Benzhydryl Compounds; Cresols; Cross-Over Studies; Double-Blind Method; Female; Humans; Male;	2004
Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. The Journal of urology, 2005, Volume: 173, Issue:1 Topics: Adolescent; Anti-Infective Agents, Urinary; Child; Humans; Mandelic Acids; Reflex, Abnormal; Tablets	2005
Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. European urology, 2007, Volume: 51, Issue:1 Topics: Adolescent; Adult; Aged; Benzilates; Cholinergic Antagonists; Double-Blind Method; Female; Humans; M	2007
Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. The Journal of urology, 2007, Volume: 177, Issue:1 Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Atropine; Cross-Over Studies; Doubl	2007
The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury. TheScientificWorldJournal, 2007, Oct-22, Volume: 7 Topics: Administration, Intravesical; Adolescent; Adult; Capsaicin; Drug Therapy, Combination; Female; Human	2007
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. European urology, 2008, Volume: 53, Issue:5 Topics: Adolescent; Adult; Benzhydryl Compounds; Benzilates; Cresols; Dose-Response Relationship, Drug; Drug	2008
Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clinical and experimental obstetrics & gynecology, 1984, Volume: 11, Issue:1-2 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Mandelic Acids; Manometr	1984
The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. British journal of urology, 1980, Volume: 52, Issue:6 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Mi	1980
The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Progress in clinical and biological research, 1981, Volume: 78 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Mi	1981
[The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization]. Hinyokika kiyo. Acta urologica Japonica, 1995, Volume: 41, Issue:7 Topics: Administration, Intravesical; Adolescent; Adult; Catheterization; Child; Drug Administration Schedul	1995
Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. The Journal of urology, 1996, Volume: 156, Issue:2 Pt 2 Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female;	1996
Intravesical oxybutynin for spinal cord injury patients. Spinal cord, 1996, Volume: 34, Issue:5 Topics: Adult; Aged; Cholinergic Antagonists; Humans; Injections; Mandelic Acids; Middle Aged; Spinal Cord I	1996
Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology, 1997, Volume: 50, Issue:6A Suppl Topics: Adult; Analysis of Variance; Benzhydryl Compounds; Chi-Square Distribution; Cholinergic Antagonists;	1997
Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction. Spinal cord, 1998, Volume: 36, Issue:6 Topics: Adult; Female; Humans; Injections; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Quality of	1998
Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. European urology, 1998, Volume: 34, Issue:2 Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female;	1998
Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. The Journal of urology, 1998, Volume: 160, Issue:3 Pt 2 Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Drug Sta	1998
Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. International urogynecology journal and pelvic floor dysfunction, 1999, Volume: 10, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Double-Blind	1999
Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology, 2000, Volume: 55, Issue:3 Topics: Administration, Intravesical; Administration, Oral; Adolescent; Cholinergic Antagonists; Female; Hum	2000
Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal cord, 2000, Volume: 38, Issue:4 Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Cholinergic Antagonists; C	2000
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clinic proceedings, 2001, Volume: 76, Issue:4 Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Double-Blind Method; Drug Administ	2001
Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. The Journal of urology, 2001, Volume: 165, Issue:5 Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Male; M	2001
Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scandinavian journal of urology and nephrology, 2002, Volume: 36, Issue:1 Topics: Administration, Intravesical; Adolescent; Adult; Cholinergic Antagonists; Cross-Over Studies; Double	2002
[Assessment of the use of oxybutynin hydrochloride (Pollakisu tablets) in the elderly]. Hinyokika kiyo. Acta urologica Japonica, 1991, Volume: 37, Issue:9 Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Aged; Paras	1991
Idiopathic bladder hyperactivity treated with Ditropan (oxybutynin chloride). International urology and nephrology, 1990, Volume: 22, Issue:6 Topics: Drug Evaluation; Female; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholytics; Urinary Blad	1990
[Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder]. Hinyokika kiyo. Acta urologica Japonica, 1989, Volume: 35, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Drug Evaluation; Female; Humans; Male; Mandelic A	1989
[Clinical effects of oxybutynin hydrochloride on neurogenic bladder]. Hinyokika kiyo. Acta urologica Japonica, 1986, Volume: 32, Issue:6 Topics: Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Male; Mandelic	1986
Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. The Journal of urology, 1986, Volume: 135, Issue:5 Topics: Female; Humans; Male; Mandelic Acids; Multiple Sclerosis; Parasympatholytics; Propantheline; Prospec	1986

Article	Year
1,5-Benzodioxepin derivatives as a novel class of muscarinic M3 receptor antagonists. Bioorganic & medicinal chemistry letters, 2007, Feb-15, Volume: 17, Issue:4 Topics: Animals; Binding, Competitive; Cell Line; Humans; Indicators and Reagents; Insecta; Mandelic Acids;	2007
Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder. Topics in spinal cord injury rehabilitation, 2022,Summer, Volume: 28, Issue:3 Topics: Child; Female; Humans; Male; Mandelic Acids; Retrospective Studies; Spinal Cord Injuries; Urinary Bl	2022
How early is early? Effect of oxybutynin on bladder dynamics within the first year of life in patients with spina bifida. Journal of pediatric urology, 2020, Volume: 16, Issue:2 Topics: Child; Follow-Up Studies; Humans; Infant; Mandelic Acids; Retrospective Studies; Spinal Dysraphism;	2020
Case Presentation: Neurogenic Bladder in a Girl After Surgery for Cloacal Malformation. European urology focus, 2017, Volume: 3, Issue:2-3 Topics: Acetylcholine Release Inhibitors; Administration, Intravesical; Botulinum Toxins, Type A; Child; Chi	2017
Can Oral Fesoterodine Be an Alternative for Intravesical Oxybutynin Instillations in Children with Neuropathic Bladder Dysfunction? Urologia internationalis, 2019, Volume: 103, Issue:2 Topics: Administration, Intravesical; Administration, Oral; Adolescent; Benzhydryl Compounds; Child; Child,	2019
Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia. International urology and nephrology, 2013, Volume: 45, Issue:3 Topics: Administration, Oral; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Mus	2013
Bladder calculus formation on the tip of a migrated disused ventriculoperitoneal shunt. Journal of pediatric surgery, 2013, Volume: 48, Issue:5 Topics: Abnormalities, Multiple; Child; Cholinergic Antagonists; Combined Modality Therapy; Cystoscopy; Equi	2013
Behavioral effects of long-term antimuscarinic use in patients with spinal dysraphism: a case control study. The Journal of urology, 2013, Volume: 190, Issue:6 Topics: Adolescent; Case-Control Studies; Child; Child Behavior; Child Behavior Disorders; Female; Humans; M	2013
Symptoms and side effects: delicate balance in the management of patients with neurogenic bladder. The Journal of urology, 2013, Volume: 190, Issue:6 Topics: Child Behavior; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Spinal Dysraphism; Uri	2013
Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourology and urodynamics, 2015, Volume: 34, Issue:4 Topics: Administration, Intravesical; Adolescent; Adult; Age Factors; Child; Child, Preschool; Diagnostic Te	2015
Upper tract changes in patients with neurogenic bladder and sustained pressures >40 cm following bladder neck surgery without augmentation. Journal of pediatric urology, 2014, Volume: 10, Issue:4 Topics: Child; Female; Follow-Up Studies; Humans; Hydronephrosis; Male; Mandelic Acids; Muscarinic Antagonis	2014
Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design. Journal of clinical pharmacology, 2014, Volume: 54, Issue:11 Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Area Under Curve; Benzhydryl Compounds; Child;	2014
A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics. BMC urology, 2014, Aug-14, Volume: 14 Topics: Adult; Botulinum Toxins, Type A; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antag	2014
Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study. Korean journal of urology, 2014, Volume: 55, Issue:12 Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Female; Humans; Infant; Infant, Newborn; Male;	2014
Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury. Neurourology and urodynamics, 2017, Volume: 36, Issue:4 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Drug Therapy, Co	2017
Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU international, 2009, Volume: 103, Issue:6 Topics: Adolescent; Benzilates; Child; Child, Preschool; Epidemiologic Methods; Female; Humans; Infant; Male	2009
Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology, 2009, Volume: 74, Issue:4 Topics: Administration, Cutaneous; Adult; Drug Dosage Calculations; Female; Humans; Male; Mandelic Acids; Mi	2009
The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. Neurourology and urodynamics, 2010, Volume: 29, Issue:3 Topics: Administration, Intravesical; Adolescent; Adult; Aged; Electrophysiological Phenomena; Female; Human	2010
Urodynamic parameters development and complications of clean intermittent self-catheterization in Chinese schoolchildren with neurogenic underactive bladder. Urologia internationalis, 2011, Volume: 86, Issue:4 Topics: Child; Child, Preschool; China; Female; Fever; Follow-Up Studies; Humans; Male; Mandelic Acids; Spin	2011
Detrusorectomy reduces the need for augmentation and use of antimuscarinics in children with neuropathic bladders. Journal of pediatric urology, 2013, Volume: 9, Issue:2 Topics: Adolescent; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Muscar	2013
Significance of low compliance bladder in cauda equina injury. Spinal cord, 2002, Volume: 40, Issue:12 Topics: Administration, Intravesical; Administration, Oral; Adult; Benzilates; Cauda Equina; Compliance; Fem	2002
Urodynamics in a rat neurogenic bladder model with a unilateral electrolytic lesion of the basal forebrain. BJU international, 2003, Volume: 91, Issue:9 Topics: Animals; Benzilates; Brain Diseases; Cholinergic Antagonists; Disease Models, Animal; Fumarates; Mal	2003
[Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder]. Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica, 2005, Volume: 18, Issue:1 Topics: Child; Cholinergic Antagonists; Drug Administration Schedule; Electrocardiography; Humans; Infant; M	2005
Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele. The Journal of urology, 2007, Volume: 178, Issue:4 Pt 1 Topics: Adolescent; Child; Cholinergic Antagonists; Female; Follow-Up Studies; Humans; Hydronephrosis; Kidne	2007
The durability of intravesical oxybutynin solutions over time. The Journal of urology, 2007, Volume: 178, Issue:4 Pt 2 Topics: Administration, Intravesical; Anti-Bacterial Agents; Chromatography, Gas; Drug Stability; Humans; Hy	2007
Urodynamic findings and long-term outcome management of patients with multiple sclerosis-induced lower urinary tract dysfunction. The Journal of urology, 1984, Volume: 132, Issue:4 Topics: Adult; Aged; Bethanechol; Bethanechol Compounds; Female; Humans; Imipramine; Male; Mandelic Acids; M	1984
The uninhibited bladder in children: effect of treatment on recurrence of urinary infection and on vesicoureteral reflux resolution. The Journal of urology, 1983, Volume: 130, Issue:6 Topics: Adolescent; Anti-Infective Agents, Urinary; Child; Child, Preschool; Drug Combinations; Female; Huma	1983
The uninhibited bladder in children: effect of treatment on vesicoureteral reflux resolution. Contributions to nephrology, 1984, Volume: 39 Topics: Adolescent; Anti-Infective Agents, Urinary; Child; Child, Preschool; Female; Humans; Male; Mandelic	1984
Oxybutynin Chloride (Ditrophan)--clinical uses and limitations. Paraplegia, 1980, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Middle Aged	1980
Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents. Neurourology and urodynamics, 1995, Volume: 14, Issue:2 Topics: Adrenergic alpha-Antagonists; Animals; Autonomic Nervous System Diseases; Calcium Channel Blockers;	1995
Intravesical oxybutinin chloride in children with intermittent catheterization: sonographic findings. Pediatric radiology, 1994, Volume: 24, Issue:5 Topics: Administration, Intravesical; Child; Female; Humans; Male; Mandelic Acids; Meningomyelocele; Parasym	1994
Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. Paraplegia, 1994, Volume: 32, Issue:1 Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids; Meningomyelocele;	1994
Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients. The Journal of urology, 1994, Volume: 151, Issue:4 Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Female; Follow-Up Studies;	1994
Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity. British journal of urology, 1993, Volume: 72, Issue:5 Pt 2 Topics: Administration, Intravesical; Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Mand	1993
[Topical treatment with oxybutynin chloride in neurogenic incontinence]. Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica, 1993, Volume: 6, Issue:1 Topics: Administration, Topical; Adolescent; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids;	1993
Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results. European urology, 1995, Volume: 28, Issue:4 Topics: Administration, Intravesical; Administration, Oral; Humans; Mandelic Acids; Parasympatholytics; Urin	1995
Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy. European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie, 1995, Volume: 5 Suppl 1 Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Combined	1995
Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. The Journal of urology, 1996, Volume: 156, Issue:4 Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Female; Humans; Infant; Male; Man	1996
[Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects]. Lakartidningen, 1996, Oct-09, Volume: 93, Issue:41 Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female;	1996
Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. The Journal of urology, 1997, Volume: 157, Issue:2 Topics: Administration, Intravesical; Child; Child, Preschool; Cholinergic Antagonists; Humans; Mandelic Aci	1997
In-vivo whole bladder response to anticholinergic and musculotropic agents in spinal cord injured rats. The journal of spinal cord medicine, 1997, Volume: 20, Issue:1 Topics: Animals; Cholinergic Antagonists; Dose-Response Relationship, Drug; Flavoxate; Male; Mandelic Acids;	1997
Intravesical therapy for the treatment of neurogenic bladder in children. The Australian and New Zealand journal of surgery, 1997, Volume: 67, Issue:10 Topics: Administration, Intravesical; Child; Child, Preschool; Cholinergic Antagonists; Drug Therapy, Combin	1997
The role of oxybutynin in spinal cord injured patients with indwelling catheters. The Journal of urology, 1997, Volume: 158, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Cholinergic Antagonists; Humans; Male; Mandel	1997
Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. The Journal of urology, 1998, Volume: 160, Issue:3 Pt 1 Topics: Administration, Intravesical; Administration, Oral; Adolescent; Child; Child, Preschool; Cholinergic	1998
Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. British journal of urology, 1998, Volume: 82, Issue:6 Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Female; Humans; Infant; Male; Man	1998
Clinical efficacy of oxybutynin on sensory urgency as compared with that on motor urgency. Urologia internationalis, 1999, Volume: 62, Issue:1 Topics: Aged; Cholinergic Antagonists; Humans; Mandelic Acids; Muscle Contraction; Muscle, Smooth; Severity	1999
Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. The Journal of urology, 1999, Volume: 162, Issue:3 Pt 2 Topics: Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Female; Follow-Up Studies; Humans; Inf	1999
Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU international, 2001, Volume: 87, Issue:7 Topics: Administration, Intravesical; Administration, Oral; Child; Child, Preschool; Cholinergic Antagonists	2001
Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. The Journal of urology, 2001, Volume: 166, Issue:6 Topics: Administration, Intravesical; Adolescent; Adult; Cholinergic Antagonists; Diffusion; Electrochemistr	2001
Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology, 2002, Volume: 59, Issue:3 Topics: Adolescent; Child; Child, Preschool; Delayed-Action Preparations; Humans; Mandelic Acids; Retrospect	2002
Assessment and conservative management of the neuropathic bladder. Seminars in pediatric surgery, 2002, Volume: 11, Issue:2 Topics: Benzhydryl Compounds; Child; Child, Preschool; Cholinergic Antagonists; Cresols; Female; Humans; Inf	2002
Follow-up of clean intermittent catheterization for children with neurogenic bladders. Urology, 1992, Volume: 40, Issue:6 Topics: Adolescent; Child; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Meningomyelocele; Parasy	1992
Neuropathic urinary incontinence in pediatric patients: management with artificial sphincter. Journal of pediatric surgery, 1992, Volume: 27, Issue:11 Topics: Adolescent; Adult; Female; Humans; Male; Mandelic Acids; Meningomyelocele; Parasympatholytics; Treat	1992
The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. American journal of diseases of children (1960), 1992, Volume: 146, Issue:7 Topics: Boston; Combined Modality Therapy; Female; Follow-Up Studies; Hospitals, Pediatric; Humans; Hydronep	1992
The pharmacokinetics of intravesical and oral oxybutynin chloride. The Journal of urology, 1992, Volume: 148, Issue:2 Pt 2 Topics: Administration, Intravesical; Administration, Oral; Adolescent; Animals; Child; Child, Preschool; Do	1992
The use of intravesical oxybutynin chloride in children with neurogenic bladder. The Journal of urology, 1991, Volume: 146, Issue:2 ( Pt 2) Topics: Administration, Intravesical; Adolescent; Child; Child, Preschool; Female; Humans; Male; Mandelic Ac	1991
[Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence]. Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:12 Topics: Administration, Oral; Drug Administration Schedule; Drug Evaluation; Humans; Mandelic Acids; Polyuri	1990
Current management of childhood neuropathic bladder: review of 156 cases. Zeitschrift fur Kinderchirurgie : organ der Deutschen, der Schweizerischen und der Osterreichischen Gesellschaft fur Kinderchirurgie = Surgery in infancy and childhood, 1990, Volume: 45, Issue:4 Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; Ephedrine; Female; Follow-Up Studies	1990
[Clinical effect of oxybutynin hydrochloride (1 mg/tablet)]. Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Female; Humans; Male; Mandelic Acids; Middle A	1990
Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation. British journal of urology, 1990, Volume: 66, Issue:5 Topics: Combined Modality Therapy; Female; Humans; Infant, Newborn; Male; Mandelic Acids; Meningomyelocele;	1990
Comparison of calcium antagonist properties of antispasmotic agents. The Journal of urology, 1987, Volume: 138, Issue:3 Topics: Animals; Calcium; Calcium Channel Blockers; Flavoxate; Imipramine; Ion Channels; Male; Mandelic Acid	1987
In vitro intravesical instillation of anticholinergic, antispasmodic and calcium blocking agents (rabbit whole bladder model). The Journal of urology, 1989, Volume: 141, Issue:6 Topics: Administration, Intravesical; Animals; Atropine; Bethanechol; Bethanechol Compounds; Calcium Channel	1989
Topical oxybutynin chloride for relaxation of dysfunctional bladders. The Journal of urology, 1989, Volume: 141, Issue:6 Topics: Administration, Intravesical; Aged; Child; Humans; Mandelic Acids; Middle Aged; Parasympatholytics;	1989
Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. The Journal of urology, 1988, Volume: 140, Issue:1 Topics: Aged; Aged, 80 and over; Blood Pressure; Female; Heart Rate; Humans; Intraocular Pressure; Male; Man	1988
[Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial]. Hinyokika kiyo. Acta urologica Japonica, 1988, Volume: 34, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Child	1988
[Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children]. Annales de pediatrie, 1986, Volume: 33, Issue:7 Topics: Adolescent; Child; Child, Preschool; Circadian Rhythm; Female; Humans; Imipramine; Male; Mandelic Ac	1986
[Clinical effectiveness of KL 007 (oxybutynin hydrochloride) in urinary disorders]. Hinyokika kiyo. Acta urologica Japonica, 1985, Volume: 31, Issue:12 Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Humans; Male; Mandelic Acids; Manometry; Middle Ag	1985
Clinical reevaluation of the effect of oxybutynin chloride on uninhibited neurogenic and reflex neurogenic bladder. Urologia internationalis, 1986, Volume: 41, Issue:1 Topics: Aged; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscle, Smooth; Parasympatholytics; Pilot P	1986
Radioisotope renography in spinal cord injury. The Journal of urology, 1985, Volume: 133, Issue:2 Topics: Adult; Humans; Male; Mandelic Acids; Middle Aged; Radioisotope Renography; Retrospective Studies; Sp	1985
Effects of oxybutynin on vesicoureteral reflux in children. The Journal of urology, 1985, Volume: 134, Issue:6 Topics: Child; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Mandelic Acids; Parasympatholytics	1985

oxybutynin and Urinary Bladder, Neurogenic